Search results
Zhi-Hong Wu Background The CRISPR/dCas9 system is a powerful tool to activate the transcription of target genes in eukaryotic or prokaryotic cells, but lacks assays in complex conditions, such as ...
Zhi-Hong WU | Cited by 1,788 | of Shandong University, Jinan (SDU) | Read 163 publications | Contact Zhi-Hong WU
Zhi-hong Wu's 104 research works with 1,064 citations and 3,845 reads, including: Spatial region-resolved proteome map reveals mechanism of COVID-19-associated heart injury
2009. Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide. KZ Hein, H Takahashi, T Tsumori, Y Yasui, Y Nanjoh, T Toga, Z Wu, ... Proceedings of the National Academy of Sciences 112 (42), 13039-13044.
The publisher, Zhejiang People’s Publishing House, pulled Wu’s book off shelves in both physical and online stores in China in mid-February. A staffer with the publisher said that the removal ...
Jan 10, 2022 · Zhi Qi, Zihan Xu, Liuzhen Zhang, Yongkang Zou, Jinping Li, Wenyu Yan, Cheng Li & Hong Wu Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
Oct 17, 2020 · Prostate cancers generally lack T cell infiltration and display resistance to immune checkpoint therapies (ICT). We found that intermittent but not daily dosing of PI3Kα/β/δ inhibitor BAY1082439 on a Pten -null spontaneous prostate cancer model could overcome ICT resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo . Mechanistically, BAY1082439 converts Pten -null cancer cell-intrinsic immune-suppression to immune-stimulation by promoting IFNα/γ pathway activation ...
